Xie L - Search Results

1

Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A.

Xue F, Zhao X, Sun J, Zeng X, Yang F, Xu M, Yu Z, Gu W, Feng Y, Li W, Zheng C, Bi H, Xie L, Gai W, Yang R. Xue F, et al. Among authors: xie l. Haemophilia. 2021 Sep;27(5):814-822. doi: 10.1111/hae.14350. Epub 2021 Jun 5. Haemophilia. 2021. PMID: 34089210 Clinical Trial.

2

Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice.

Gu RL, Liu L, Xie LZ, Gai WL, Cao SS, Meng ZY, Gan H, Wu ZN, Li J, Zheng Y, Zhu XX, Dou GF. Gu RL, et al. Among authors: xie lz. Acta Pharmacol Sin. 2016 Mar;37(3):408-14. doi: 10.1038/aps.2015.121. Epub 2016 Jan 25. Acta Pharmacol Sin. 2016. PMID: 26806305 Free PMC article.

3

Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma.

Gui L, Han X, He X, Song Y, Yao J, Yang J, Liu P, Qin Y, Zhang S, Zhang W, Gai W, Xie L, Shi Y. Gui L, et al. Among authors: xie l. Chin J Cancer Res. 2016 Apr;28(2):197-208. doi: 10.21147/j.issn.1000-9604.2016.02.07. Chin J Cancer Res. 2016. PMID: 27199517 Free PMC article.

4

Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma.

Bai M, Wang M, Deng T, Bai Y, Zang K, Miao Z, Gai W, Xie L, Ba Y. Bai M, et al. Among authors: xie l. Cancer Biol Med. 2022 Jan 12;19(3):358-69. doi: 10.20892/j.issn.2095-3941.2021.0388. Online ahead of print. Cancer Biol Med. 2022. PMID: 35014769 Free PMC article.

5

Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A.

Wu R, Wang X, Zhao X, Cheng Y, Zhou Z, Sun J, Xu M, Li W, Xiao J, Yang F, Chen Y, Xu W, Huang J, Ma C, Gai W, Xie L, Yang R. Wu R, et al. Among authors: xie l. Haemophilia. 2022 Nov;28(6):e199-e208. doi: 10.1111/hae.14622. Epub 2022 Jul 8. Haemophilia. 2022. PMID: 35802040

6

Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera^® ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial.

Shi Y, Zhang Q, Hong X, Wang Z, Gao Y, Zou L, Cen H, Gui L, Li Y, Feng J, Wang Z, Zhang M, Jin C, Zhang W, Hu J, Zheng C, Zheng Z, Zhang L, Chen S, Huang Y, Tang Y, Gao Y, Hao M, Li X, Chang C, Yang H, Wu H, Shen L, Ke X, Zhang L, Xi Y, Yang L, Xie L, Gai W, Ji Y. Shi Y, et al. Among authors: xie l. Hematol Oncol. 2022 Dec;40(5):930-940. doi: 10.1002/hon.3054. Epub 2022 Aug 12. Hematol Oncol. 2022. PMID: 35858181 Clinical Trial.

7

Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study.

Zhang W, Han X, Yang L, Song Y, Xie L, Gai W, Wang Y, Shi Y. Zhang W, et al. Among authors: xie l. BMC Cancer. 2022 Oct 28;22(1):1104. doi: 10.1186/s12885-022-10147-9. BMC Cancer. 2022. PMID: 36307775 Free PMC article. Clinical Trial.

8

A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera^®) in patients with CD20-positive B-cell non-Hodgkin lymphoma.

Han X, Zhang M, Wang H, Zhang Q, Li W, Hao M, Gao Y, Jin J, Ren H, Tang Y, Hong X, Ke X, Su H, Gui L, Luo J, Xie L, Gai W, Shi Y. Han X, et al. Among authors: xie l. Chin J Cancer Res. 2022 Dec 30;34(6):601-611. doi: 10.21147/j.issn.1000-9604.2022.06.08. Chin J Cancer Res. 2022. PMID: 36714342 Free PMC article.

9

Validation of Luminex immunological and competitive Luminex immunological assays for clinical immunogenicity assessment of a 14-valent recombinant human papillomavirus vaccine.

Zhang X, Meng D, Li H, Li X, Li J, Hu P, Zhao L, Wang R, Zhao C, Luo C, Gu W, Gai W, Wang Y, Xie L. Zhang X, et al. Among authors: xie l. J Med Virol. 2023 Aug;95(8):e29050. doi: 10.1002/jmv.29050. J Med Virol. 2023. PMID: 37635425

10

Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial.

Hannawi S, Yan L, Saifeldin L, Abuquta A, Alamadi A, Mahmoud SA, Hassan A, Zhang M, Gao C, Chen Y, Gai W, Xie L. Hannawi S, et al. Among authors: xie l. EClinicalMedicine. 2023 Sep 8;64:102195. doi: 10.1016/j.eclinm.2023.102195. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37731938 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13,064 results

Search Page

Filters